Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bayer divests its plasma unit to US investors

Executive Summary

Bayer AG has agreed to sell the plasma products business of Bayer Biological Products, a division of its US subsidiary Bayer HealthCare, to a newly formed company (initially called NPS BioTherapeutics) controlled by affiliates of the private US investment groups Cerberus Capital Management and Ampersand Ventures. The total consideration is €450mm ($590mm) in cash, a 10% stake in NPS, and potential earn-outs of up to $60mm.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies